Olympic athletes overcome health challenges to reach the pinnacle of their sport

The athletes have done the training and achieved their dreams, a trip to the Paris Olympics set to begin Friday July 26th.

DFG funds new clinical research unit to study autoimmune-mediated neurological diseases

How do neurological disorders arise that are caused, triggered, or influenced by antibodies? What better possibilities are there for diagnosis – and above all for

July 15, 2023

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research’s Pitch, Deep Dive and Q&A Webinar on April 16th, 2024 | Psychedelic Invest

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite investors and

April 11, 2024

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders | Psychedelic Invest

SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel

November 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.